Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes

Haak, Thomas
January 2015
Clinical Medicine Insights: Endocrinology & Diabetes;2015, Issue 8, p1
Academic Journal
Type 2 diabetes mellitus (T2DM) is a progressive condition requiring long-term treatment. Most patients with T2DM are unable to maintain normoglycemia using metformin alone; thus, combination therapy is a pivotal part of disease management. Addition of the dipeptidyl peptidase-4 inhibitor linagliptin, with its proven efficacy, low propensity for hypoglycemia, and weight neutrality, has been shown to improve glycemic control for patients who are not well controlled with metformin. As patients often have other comorbidities requiring pharmacotherapy, an increase in pill number, different prescribing frequencies, and timing of medications may adversely impact patients' adherence. Studies have shown that treatment nonadherence contributes to increased morbidity, mortality, and healthcare cost. In the United States, the single-pill combination (SPC) of linagliptin/metformin is available in three strengths approved for twice-daily administration: 2.5/500 mg, 2.5/850 mg, and 2.5/1000 mg. The SPC has the potential to reduce pill burden and simplify patients' treatment regimens, thereby promoting improved adherence and efficacy.


Related Articles

  • Industry update.  // Diabetes Digest;2015, Vol. 14 Issue 3, p148 

    The article offers health news briefs related to diabetes management. Among the topics mentioned include the positive results of the combined metformin and empagliflozin drugs by pharmaceutical company Eli Lilly and Co. for type diabetes treatment, the availability of Toujeo® basal insulin...

  • Sitagliptin/metformin fixed-dose combination: a guide to its use in type 2 diabetes mellitus.  // Drugs & Therapy Perspectives;Sep2011, Vol. 27 Issue 9, p1 

    Sitagliptin/metformin is an effective and well tolerated option in the treatment of type 2 diabetes mellitus. In clinical trials in patients with type 2 diabetes, combination therapy with sitagliptin plus metformin improved glycaemic control, including in patients inadequately controlled with...

  • A CONVERSATION About Janumet and Earlier Combination Therapy for Type 2 Diabetes ... Sethu K. Reddy. Al-Samarrie, Nadia // Diabetes Health;Oct/Nov2011, Vol. 20 Issue 5, p16 

    An interview with Sethu K. Reddy, vice-president of U.S. medical affairs for Merck and former chairman of Endocrinology, Diabetes and Metabolism, at Cleveland Clinic in Ohio, is presented. Reddy talks about the antidiabetic drug Janumet, a combination of metformin and Merck's DPP-4 inhibitor,...

  • Updated Review: Improved Glycemic Control with Repaglinide-Metformin in Fixed Combination for Patients with Type 2 Diabetes. Richard III, John W.; Raskin, Philip // Clinical Medicine Insights: Endocrinology & Diabetes;2011, Issue 4, p29 

    As the prevalence of type 2 diabetes continues to rise, new drug therapies will need to be explored to prevent morbidity and mortality associated with diabetes as well as growing health care costs. Type 2 diabetes is characterized by decreased insulin secretion and sensitivity. Numerous oral...

  • Glycaemic control improved with dapagliflozin plus SU.  // Diabetes Digest;2012, Vol. 11 Issue 1, p26 

    The article focuses on a study which investigated the safety, tolerability, and efficacy of dapagliflozin (dapa) with glimepiride in persons with poorly controlled type 2 diabetes (T2D).

  • Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus. Patel, Manav B.; Elmore, Lindsey K.; Edgerton, Lisa P.; Whalin, Laurie M. // American Journal of Health-System Pharmacy;6/15/2012, Vol. 69 Issue 12, p1044 

    Purpose. The case of a patient with type 2 diabetes mellitus who received combination exenatide-sitagliptin with glipizide is reported. Summary. A 55-year-old, 204-lb Caucasian woman arrived at a clinic with polydipsia. Her blood glucose concentration was 450 mg/dL and her glycosylated...

  • Acute myocardial infarction associated to DPP-4 inhibitors. Nunes, J. P. L.; Rodrigues, J. D.; Melão, F. // Heart, Lung & Vessels;2014, Vol. 6 Issue 3, p180 

    No abstract available.

  • Efficacy of secondline therapies added to metformin in T2D.  // Diabetes Digest;2012, Vol. 11 Issue 3, p143 

    The article discusses a study conducted by S. C. Liu, Y. K. Tu, M. N. Chien and colleagues comparing the efficacy of second-line antidiabetes drugs in people with T2D taking metformin.

  • Efficacy of triple oral polypill for people with T2D.  // Diabetes Digest;2012, Vol. 11 Issue 1, p25 

    The article focuses on the study which focuses on the comparison of the efficacy of a fixed-dose triple oral diabetes Polypill and 500 milligrams (mg) sustained-release metformin in patients with type 2 diabetes (T2D) conducted by D. S. Bell and colleagues.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics